
Premium content
Access to this content requires a subscription. You must be a premium user to view this content.

poster
Associations between Rheumatic Diseases and Mental Health Disorders
Background: Rheumatic diseases are frequently linked to a reduced quality of life (QoL), particularly as disease severity escalates. Patients with rheumatic conditions often have higher rates of depression and anxiety, conditions which can diminish QoL and hinder medication adherence. Suboptimal medication adherence to disease-modifying antirheumatic drugs agents can allow disease progression, exacerbating both QoL and mental health. However, the relationship between rheumatic diseases and mental health disorders remains unclear.
Methods: This retrospective case-control study examined the association between rheumatic diseases—specifically rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriatic arthritis (PsA), and ankylosing spondylitis (AS)—and mental health disorders (anxiety and depression) in patients treated within the authors' health system. Patients over 18 years old between September 28, 2010, and May 1, 2024 were identified using Epic’s SlicerDicer tool. Rheumatic diseases and mental health disorders were identified using ICD-10 codes. Odds ratios (OR) and 95% confidence intervals were calculated via multivariable logistic regression, adjusting for sex and age using IBM SPSS Statistics 29.0.2.
Results: Of the 3,305,015 patients screened, 1.0% had RA, 0.3% had SLE, 0.2% had PsA, and 0.1% had AS. Anxiety was identified in 12.3% patients, and depression in 11.9%. Adjusting for age and sex, patients with diagnosis codes for RA, SLE, PsA, and AS had a statistically significant increase in the odds for anxiety (ORs ranging from 1.99 to 2.40 ), depression (ORs ranging from 2.07 to 2.67), and concomitant anxiety and depression (ORs ranging from 2.37 to 3.09), with all p-values < 0.001. Subgroup analysis of patients seen specifically at our outpatient rheumatology clinics revealed associations between SLE and anxiety, depression, and concomitant anxiety and depression (ORs 1.42, 1.38, 1.49, respectively, all p-values <0.001). PsA and AS were linked to depression (ORs 1.18, p=0.008 and 1.32, p=0.003, respectively) and concomitant anxiety and depression (ORs 1.17, p=0.034 and 1.40, p=0.004, respectively). The lower ORs in this subgroup are likely due to underreporting of ICD-10 codes for depression and anxiety, as these patients may receive mental health care outside of the health system.
Conclusion: Patients with rheumatic disease face significantly increased incidence of depression and anxiety, negatively impacting QoL and medication adherence. It is essential to frequently screen these patients for mental health conditions to ensure comprehensive care.